We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Rebiotix and Ferring Pharmaceuticals have unveiled positive preliminary findings from an ongoing pivotal late-stage trial of the investigational microbiome-based treatment RBX2660.